Takeda Pharmaceutical (TKPHF) Income from Non-Controlling Interests (2017 - 2026)

Takeda Pharmaceutical's Income from Non-Controlling Interests history runs 10 years deep, the most recent figure standing at $395346.1 for Q1 2026.

• In Q1 2026, Income from Non-Controlling Interests rose 160.32% year-over-year to $395346.1; the TTM figure through Mar 2026 stood at -$2.3 million (up 1.01% YoY), while the FY2026 annual figure was $8.0 million, up 36.58% from the prior year.
• Income from Non-Controlling Interests was $395346.1 for Q1 2026 at Takeda Pharmaceutical, up from -$649790.1 in the prior quarter.
• In the past five years, Income from Non-Controlling Interests ranged from a high of $395346.1 in Q1 2026 to a low of -$1.4 million in Q3 2025.
• Historically, Income from Non-Controlling Interests has averaged -$313998.4 across 5 years, with a median of -$109344.0 in 2022.
• The sharpest annual moves came in 2024 and 2025: Income from Non-Controlling Interests surged 308.17% in 2024, then plunged 504.74% in 2025.
• A 5-year view of Income from Non-Controlling Interests shows it stood at $155723.0 in 2022, then plunged by 48.46% to $80266.1 in 2023, then tumbled by 919.5% to -$657777.5 in 2024, then gained by 1.21% to -$649790.1 in 2025, then jumped by 160.84% to $395346.1 in 2026.
• The last three Income from Non-Controlling Interests figures came in at $395346.1 (Q1 2026), -$649790.1 (Q4 2025), and -$1.4 million (Q3 2025), per Business Quant data.